Workplace impacts of anti-TNF therapies in rheumatoid arthritis: Review of the literature

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 2, 2009, Pages 255-269

  Birnbaum, Howard ^a   Shi, Lizheng ^b   Pike, Crystal ^a   Kaufman, Rebecca ^a   Sun, Peter ^c   Cifaldi, Mary ^d  

^a ANALYSIS GROUP   (United States)

^b TULANE UNIVERSITY   (United States)

^c Kailo Research Group   (United States)

^d ABBOTT LABORATORIES   (United States)

Author keywords

Economic burden; Employer costs; Productivity; Rheumatoid arthritis; Workplace

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ABSENTEEISM; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; COST; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; ECONOMIC EVALUATION; EMPLOYEE; EMPLOYER; FUNCTIONAL STATUS; HEALTH CARE COST; HUMAN; JOB PERFORMANCE; JOB SATISFACTION; LONG TERM CARE; MEDICAL LEAVE; MONOTHERAPY; PRODUCTIVITY; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WORK CAPACITY; WORK DISABILITY; WORKPLACE; DRUG ANTAGONISM; DRUG COMBINATION; ECONOMICS; RANDOMIZED CONTROLLED TRIAL;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HEALTH CARE COSTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WORKPLACE;

EID: 65649102659     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560802682163     Document Type: Review

References (83)

1. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41 (5): 778-799 (Pubitemid 28225778)
2. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004;22 (2 Suppl 1): 1-12 (Pubitemid 38269929)
3. Theis KA, Murphy L, Hootman JM, et al. Prevalence and correlates of arthritis-attributable work limitation in the US population among persons aged 18-64: 2002 National Health Interview Survey Data. Arthritis Rheum 2007;57(3):355-363
4. Yelin E, Callahan LF. The economic cost and social and psychological impact of musculoskeletal conditions. National Arthritis Data Work Groups. Arthritis Rheum 1995;38:1351-1362
5. Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol 1996;23(Suppl 44):47-51 (Pubitemid 26094647)
6. Pugner KM, Scott DI, Holmes JW, et al. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 2000;29(5):305-320 (Pubitemid 30235982)
7. Geuskens GA, Burdorf A, Hazes JMW. Consequences of rheumatoid arthritis for performance of social roles: a literature review. J Rheumatol 2007;34(6):1248-1260 (Pubitemid 46898105)
8. Zirkzee EJM, Sneep AC, DE Buck PD, et al. Sick leave and work disability in patients with early arthritis. Clin Rheumatol 2008;27(1):1-9 (Pubitemid 350182672)
9. Shanahan EM, Smith MD. Rheumatoid arthritis, disability and the workplace. Baillieres Best Pract Res Clin Rheumatol 1999;13(4):675-688 (Pubitemid 30050435)
10. Maetzel A, Li LC, Pencharz J, et al. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 2004;63(4):395-401 (Pubitemid 38453305)
11. Shanahan EM, Smith M, Roberts-Thomson L, et al. Influence of rheumatoid arthritis on work participation in Australia. Intern Med J 2008;38(3):166-173 (Pubitemid 351271399)
12. Sokka T. Work disability in early rheumatoid arthritis. Clin Exp Rheumatol 2003;21(5 Suppl 31):S71-4 (Pubitemid 37265592)
13. Yelin EH. Musculoskeletal conditions and employment. Arthritis Care Res 1995;8:311-317 (Pubitemid 26021967)
14. Sokka T, Pincus T. Markers for work disability in rheumatoid arthritis. J Rheumatol 2001;28:1718-1722 (Pubitemid 32660653)
15. Yelin E, Henke C, Epstein W. The work dynamics of the person with rheumatoid arthritis. Arthritis Rheum 1987;30:507-512 (Pubitemid 17108103)
16. Pincus T, Callahan LF, Sale WG, et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27:864-872 (Pubitemid 14067781)
17. Fex E, Larsson B, Nived K, et al. Effect of rheumatoid arthritis on work status and social and leisure time activities in patients followed 8 years from onset. J Rheumatol 1998;25:44-50 (Pubitemid 28060116)
18. Wolfe F, Hawley D. The long-term outcomes of rheumatoid arthritis: work disability: a prospective 18 year study of 823 patients. J Rheumatol 1998;25:2108-2117 (Pubitemid 28505855)
19. Yelin E. Work disability in rheumatic diseases. Curr Opin Rheumatol 2007;19(2):91-96 (Pubitemid 46208763)
20. Reisine S, Fifield J, Walsh S, et al. a survival analysis. Arthritis Rheum 2007;57(3):372-380
21. Scott DL, Lempp HK. Outcomes associated with early rheumatoid arthritis. Expert Rev Pharmacoeconomics Outcomes Res 2006;6(5):495-508 (Pubitemid 44741601)
22. Moreland LW. Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis. Pharmacoeconomics 2004;22(2 Suppl):39-53 • A review of the early TNF-antagonist literature. (Pubitemid 38292036)
23. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-TNF monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum 2003;48:35-45
24. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti-TNF monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (safety trial of adalimumab in rheumatoid arthritis). J Rheumatol 2003;30:2563-2571 (Pubitemid 37549331)
25. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study. A multi-centre, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54(1):26-37
26. Maini RN, StClair EW, Breedveld FC, et al. For the Attract Study Group: Infliximab (chimeric anti-TNF monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. Lancet 1999;354:1932-1939
27. Lipsky P, Van Der Heijde DM, St Clair EW, et al. For the ATTRACT Study Group: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-1602
28. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-1593 (Pubitemid 32162981)
29. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis. Two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-1450
30. Toussirot É, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an update. Expert Opin Pharmacother 2007;8(13):2089-2107 • A review that summarizes the clinical literature regarding TNF antagonists. (Pubitemid 47505587)
31. Geborek P, Eberhardt KB, Larsson B, et al. Etanercept and infliximab treatment improves working capacity in arthritis patients [abstract FRI0038]. Presented at EULAR, Stockholm, Sweden; 12-15 June, 2002
32. Kavanaugh A, Han C, Bala M, et al. Successful treatment improves employability in patients with rheumatoid arthritis [abstract]. Presented at EULAR, Stockholm, Sweden; 2002
33. Yelin E, Katz P, Lubeck D, et al. Impact of etanercept (Enbrel) on health care utilization and employment among persons with early rheumatoid arthritis [abstract]. EULAR, Stockholm, Sweden; 2002
34. Lacaille D. Arthritis and employment research: Where are we? Where do we need to go? J Rheumatol 2005;32(72):42-45
35. Kessler RC, Maclean JR, Petukhova M, et al. The effects of rheumatoid arthritis on labor force participation, work performance, and healthcare costs in two workplace samples. J Occup Environ Med 2008;50(1):88-98
36. Ozminkowski RJ, Burton W N, Goetzel RZ, et al. The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits. J Occup Environ Med 2006;48(2):135-148 (Pubitemid 43237945)
37. Wolfe F, Michaud K, Strand V. Expanding the definition of clinical differences: From minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. J Rheumatol 2005;32(4):583-589 (Pubitemid 40524688)
38. Verstappen SM, Boonen A, Bijlsma J, et al. Working status among Dutch patients with rheumatoid arthritis: Work disability and working conditions. Rheumatology 2005;44(2):202-206 (Pubitemid 40277404)
39. Eberhardt K, Larsson BM, Nived K, et al. Work disability in rheumatoid arthritis: Development over 15 years and evaluation of predictive factors over time. J Rheumatol 2007;34(3):481-487 (Pubitemid 46364001)
40. Merkesdal S, Ruof J, Schoffski O, et al. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 2001;44(3):528-534 (Pubitemid 32234610)
41. Merkesdal S, Ruof J, Huelsemann JL, et al. Indirect costs assessment in patients with rheumatoid arthritis: comparison of data from the health economic patient questionnaire HEQ-RA and insurance claims data. Arthritis Rheum 2005;53(2):234-240 (Pubitemid 40530164)
42. Leardini G, SalaffiF, Montanelli R, et al. A multicenter cost-of-illness study on rheumatoid arthritis in Italy. Clin Exp Rheumatol 2002;20(4):505-515 (Pubitemid 34846625)
43. Birnbaum HG, Barton M, Greenberg PE, et al. Direct and indirect costs of rheumatoid arthritis to an employer. J Occup Environ Med 2000;42(6):588-596 • This was the first study to examine the economic impact of RA from the perspective of the employer, and includes absenteeism and disability measures. (Pubitemid 30415312)
44. Fautrel B, Clarke AE, Guillemin F, et al. Costs of rheumatoid arthritis: New estimates from the human capital method and comparison to the willingness-to-pay method. Med Decis Making 2007;27(2):138-150 (Pubitemid 46568906)
45. Lacaille D, Sheps S, Spinelli JJ, et al. Identification of modifiable work-related factors that influence the risk of work disability in rheumatoid arthritis. Arthritis Rheum 2004;51(5):843-852 (Pubitemid 39372044)
46. Puolakka K, Kauttiainen H, Pekurinen M, et al. Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial. Ann Rheum Dis 2006;65(7):899-904
47. Fifield J, Reisine S, Sheehan TJ, et al. Gender, paid work, and symptoms of emotional distress in rheumatoid arthritis patients. Arthritis Rheum 1996;39:427-435 (Pubitemid 26085218)
48. Chorus AM, Miedema HS, Wevers CJ, et al. Labour force participation among patients with rheumatoid arthritis. Ann Rheum Dis 2000;59(7):549-554 (Pubitemid 30445835)
49. Young A, Dixey J, Cox N, et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study. Rheumatology 2000;39:6 (Pubitemid 30459945)
50. Zink A, Fischer-Betz R, Thiele K, et al. Health care and burden of illness in systemic lupus erythematosus compared to rheumatoid arthritis: results from the National Database of the German Collaborative Arthritis Centres. German Collaborative Arthritis, Centers. Lupus 2004;13(7):529-536
51. Walker N, Michaud K, Wolfe F. Work limitations among working persons with rheumatoid arthritis: results, reliability, and validity of the work limitations questionnaire in 836 patients. J Rheumatol 2005;32(6):1006-1012 (Pubitemid 40828070)
52. Lerner D, Adler DA, Chang H, et al. Unemployment, job retention, and productivity loss among employees with depression. Psychiatr Serv 2004;55(12):1371-1378 (Pubitemid 39577972)
53. Gignac MAM, Sutton D, Badley EM. Arthritis symptoms, the work environment, and the future: measuring perceived job strain among employed persons with arthritis. Arthritis Rheum 2007;57(5):738-747 (Pubitemid 46932078)
54. Nilsson I, Fitinghoff H, Lilja M. Continuing to work after the onset of rheumatoid arthritis. Work 2007;28(4):335-342 (Pubitemid 46824701)
55. Nyman A, Lund ML. Influences of the social environment on engagement in occupations: The experience of persons with rheumatoid arthritis. Scand. J Occup Ther 2007;14(1):63-72 (Pubitemid 46404295)
56. Mancuso CA, Paget SA, Charlson ME. Adaptations made by rheumatoid arthritis patients to continue working: A pilot study of workplace challenges and successful adaptations. Arthritis Care Res 2000;13(2):89-99 (Pubitemid 30751831)
57. Van Den Hout WB. De Buck PDM, Vliet Vlieland TP. Cost-utility analysis of a multidisciplinary job retention vocational rehabilitation program in patients with chronic arthritis at risk of job loss. Arthritis Rheum 2007;57(5):778-786 (Pubitemid 46932083)
58. De Buck PD, De Bock GH, Van Dijk F, et al. Sick leave as a predictor of job loss in patients with chronic arthritis. Int Arch Occup Environ Health 2006;80(2):160-170 (Pubitemid 44644638)
59. Puolakka K. Cost of Finnish statutory inpatient rehabilitation and its impact on functional and work capacity of patients with early rheumatoid arthritis: experience from the FIN-RACo trial. Scand J Rheumatol 2007;36(4):270-277 (Pubitemid 47346913)
60. Ahlgren A, Bergroth A, et al. Work resumption after vocational rehabilitation: a follow-up two years after completed rehabilitation. Work 2007;28(4):343-354 (Pubitemid 46824702)
61. Lacaille D, White MA, Blackman CL, et al. Problems faced at work due to inflammatory arthritis: new insights gained from understanding patients' perspective. Arthritis Rheum 2007;57(7):1269-1279 (Pubitemid 47585474)
62. Gobelet C, Luthi F, Al-Khodairy AT, et al. Work in inflammatory and degenerative joint diseases. Disabil Rehabil 2007;29(17):1331-1339 (Pubitemid 47342882)
63. Wolfe F, Michaud K, Choi H, et al. Household Earnings and Income Losses Among 6396 Persons with Rheumatoid Arthritis. J Rheumatol 2005;32(10):1875-1883 (Pubitemid 41429015)
64. Kochevar RJ, Kaplan RM, Weisman M. Financial and career losses due to rheumatoid arthritis: a pilot study. J Rheumatol 1997;24(8):1527-1530 (Pubitemid 27320693)
65. Puolakka K. Kauttainen H, Mottonen T, et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005;52(1):36-41 (Pubitemid 40129230)
66. Puolakka K. Kauttainen H, Mottonen T, et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum 2004;50(1):55-62 (Pubitemid 38084287)
67. Puolakka K, Kautiainen H, Mottonen T, et al. Predictors of productivity loss in early rheumatoid arthritis: a 5 year follow up study. Ann Rheum Dis 2005;64(1):130-133 (Pubitemid 40075290)
68. Vlak T, Eldar R. Disability in rheumatoid arthritis after monotherapy with DMARDs. Int J Rehabil Res 2003;26(3):207-212 (Pubitemid 37268233)
69. Nordmark B, Blomqvist P, Andersson B, et al. A two-year follow-up of work capacity in early rheumatoid arthritis: a study of multidisciplinary team care with emphasis on vocational support. Scand. J Rheumatol 2006;35(1):7-14 (Pubitemid 43247247)
70. Yelin E, Trupin L, Katz P, et al. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum 2003;48(11):3046-3054 • A study on sick leave and employment status of patients taking etanercept. (Pubitemid 37409314)
71. Smolen JS, Han C, Van Der Heijde D, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 2006;54(3):716-722 • A study on employability and work status of infliximab users.
72. Allaart CF, Breedveld FC, Dijkmans BA, et al. Treatment of recent-onset rheumatoid arthritis: lessons from the best study. J Rheumatol 2007;80:25-33 • An interesting study that finds an association between quality of life and hours worked of patients with RA taking TNF antagonists.
73. Laas K, Peltomaa R, Hautiainen H, et al. Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment. Ann Rheum Dis 2006;65:924-928 • An interesting study on work disability costs of patients with RA taking infliximab.
74. Van Vollenenhoven RF, Ferraccioli G, Breedveld F, et al. Effect of adalimumab combination therapy on work performance: results from a companion study to PREMIER [abstract]. Presented at ACR, Boston; 2007 • An interesting study finding that patients taking adalimumab miss less work than those taking methotrexate.
75. Bejarano V, Quinn MA, Conaghan PG, et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 2008;59(10):1467-1474 • A study showing that patients taking adalimumab missed less work time than those taking methotrexate.
76. Mittendorf T, Dietz B, Sterz R, et al. Personal economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective. Rheumatology 2008;47(2):188-193 (Pubitemid 351168230)
77. Halpern M, Cifaldi M, Kvien T. Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group. Ann Rheum Dis 2008; doi: 10.1136/ard.2008.092734 •• A study that finds that adalimumab-treated patients with RA are less likely to stop working than methotrexate-treated patients.
78. Zhang W, Bansback N, Guh D, et al. Short-term impact of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. J Rheumatol 2008;35(9):1729-1736 • A study that finds that adalimumab-treated patients with RA miss less work and are more productive after taking adalimumab.
79. Allaire S, Wolfe F, NIU J, et al. No evidence of reduction in premature work loss among persons with rheumatoid arthritis (RA) using anti-TNF alpha agents. ACR, Boston; 2007
80. Wolfe FS, Michaud K. The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. J Rheumatol 2007;34(11):2211-2217 (Pubitemid 350076881)
81. Kavanaugh A, Han C, Bala M, et al. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol 2004;31(5):849-855 (Pubitemid 38585806)
82. Kimel M, Cifaldi M, Chen N, et al. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol 2008;35(2):206-215 • A study that finds that adalimumab-treated patients have improvement in ability to work, job loss, and work time compared with patients taking methotrexate alone. (Pubitemid 351284438)
83. Kessler RC, Barber C, Birnbaum HG, et al. Depression in the workplace: effects on short-term disability. Health Aff 1999;18(5):163-171